Market Overview:
The global baculoviral IAP repeat containing protein 5 market is expected to register a CAGR of xx% during the forecast period 2018-2030. The market growth can be attributed to the increasing prevalence of cancer, rising R&D expenditure by key players, and technological advancements in the field of cancer treatment. Based on type, the global baculoviral IAP repeat containing protein 5 market is segmented into BKM-1740, BI-1361849, BGA-005, FL-118 and others. Among these types, BKM-1740 held a dominant share in 2017 and is projected to maintain its dominance throughout the forecast period. This can be attributed to its ability to inhibit tumor cell proliferation and induce apoptosis in various types of cancers including bone cancer, kidney cancer ovarian cancer etc. Based on application type; breast cancer accounted for a majority share in 2017 and is anticipated to maintain its dominance throughout the forecast period owing to increasing incidence rates across globe coupled with rising awareness about early detection methods among women population. However; other application segments such as ovariancancer are also expected witness significant growth during 2018 – 2030 due growing incidences rates along with technological advancements taking place within this domain .
Product Definition:
Baculoviral IAP Repeat Containing Protein 5 is a protein that is found in the baculovirus. This protein helps to protect the virus from being destroyed by the host's immune system.
BKM-1740:
BKM-1740 is a Baculovirus IAP repeat containing protein 5. It is also known as BIR1, BIR2 or MGC 8806. This virus was discovered in the year 2000 and has been reported to cause severe systemic infections in patients with weak immune responses including HIV/AIDS patients.
BI-1361849:
BI-1361849 is a Baculoviral IAP repeat containing protein 5. It's a member of the immunoglobulin superfamily and has an amino acid length of around 506 residues. The structure is characterized by two pairs of amphipathic helical domains that are connected by a flexible linker region.
Application Insights:
The bone cancer segment dominated the global market in terms of revenue generation in 2017. The high prevalence of osteoporosis coupled with rising incidence rates of bone cancer is anticipated to boost the demand for baculovirus-based iap repeat containing protein 5 drugs. Moreover, increasing research and development activities pertaining to baculovirus vector system for delivery of gene therapies into cells is expected to drive growth over the forecast period.
Owing to advancements made by researchers, several new potential applications have been identified outside Ovarian Cancer and Breast Cancer such as Kidney Cancer, which was previously considered an impossibility due to low transfection efficiency using viral vectors. Thus, it can be concluded that this virus plays a significant role in delivering genes into mammalian cells outside Ovarian Cancer and Breast Cancer application areas which will help expand its usage across various diseases during the forecast period.
Regional Analysis:
North America dominated the global market in 2017. The presence of a large number of key players, favorable government initiatives, and increasing investment by companies for the development of novel therapies are some factors contributing to its largest share. In addition, rising incidence rates due to lifestyle changes and growing consumer awareness about early diagnosis are expected to drive this regional market over the forecast period.
Asia Pacific is estimated to be one of the fastest-growing regions during the forecast period owing to high unmet clinical needs coupled with rapidly improving healthcare infrastructure in emerging countries such as China & India and other Southeast Asian nations. Furthermore, increasing investments by major pharmaceutical companies for commercializing cost-effective products will further boost growth during this timeframe. Rising incidence rates due to cancer caused by virus infection will also contribute toward regional growth rate in future years (Kumar et al., 2016).
Growth Factors:
- Increasing demand for effective anticancer drugs
- Growing prevalence of cancer
- Rising research and development expenditure in the field of cancer treatment
- Technological advancements in the field of oncology
- increasing public awareness about various types of cancers and their treatments
Scope Of The Report
Report Attributes
Report Details
Report Title
Baculoviral IAP Repeat Containing Protein 5 Market Research Report
By Type
BKM-1740, BI-1361849, BGA-005, FL-118, Others
By Application
Bone Cancer, Kidney Cancer, Ovarian Cancer, Breast Cancer, Others
By Companies
Biomics Biotechnologies Co Ltd, Bioneer Corp, Boehringer Ingelheim GmbH, Immunovaccine Inc, MimiVax LLC, Optimum Therapeutics LLC, Polyplus-Transfection SA, Stemline Therapeutics Inc, tella Inc, Vaxeal Holding SA
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
232
Number of Tables & Figures
163
Customization Available
Yes, the report can be customized as per your need.
Global Baculoviral IAP Repeat Containing Protein 5 Market Report Segments:
The global Baculoviral IAP Repeat Containing Protein 5 market is segmented on the basis of:
Types
BKM-1740, BI-1361849, BGA-005, FL-118, Others
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Bone Cancer, Kidney Cancer, Ovarian Cancer, Breast Cancer, Others
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Biomics Biotechnologies Co Ltd
- Bioneer Corp
- Boehringer Ingelheim GmbH
- Immunovaccine Inc
- MimiVax LLC
- Optimum Therapeutics LLC
- Polyplus-Transfection SA
- Stemline Therapeutics Inc
- tella Inc
- Vaxeal Holding SA
Highlights of The Baculoviral IAP Repeat Containing Protein 5 Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- BKM-1740
- BI-1361849
- BGA-005
- FL-118
- Others
- By Application:
- Bone Cancer
- Kidney Cancer
- Ovarian Cancer
- Breast Cancer
- Others
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Baculoviral IAP Repeat Containing Protein 5 Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Baculoviral IAP Repeat Containing Protein 5 is a protein that is found in the Baculovirus.
Some of the major companies in the baculoviral iap repeat containing protein 5 market are Biomics Biotechnologies Co Ltd, Bioneer Corp, Boehringer Ingelheim GmbH, Immunovaccine Inc, MimiVax LLC, Optimum Therapeutics LLC, Polyplus-Transfection SA, Stemline Therapeutics Inc, tella Inc, Vaxeal Holding SA.
1. Executive Summary
2. Assumptions and Acronyms Used
3. Research Methodology
4. Baculoviral IAP Repeat Containing Protein 5 Market Overview
4.1. Introduction
4.1.1. Market Taxonomy
4.1.2. Market Definition
4.2. Macro-Economic Factors
4.2.1. Industry Outlook
4.3. Baculoviral IAP Repeat Containing Protein 5 Market Dynamics
4.3.1. Market Drivers
4.3.2. Market Restraints
4.3.3. Opportunity
4.3.4. Market Trends
4.4. Baculoviral IAP Repeat Containing Protein 5 Market - Supply Chain
4.5. Global Baculoviral IAP Repeat Containing Protein 5 Market Forecast
4.5.1. Baculoviral IAP Repeat Containing Protein 5 Market Size (US$ Mn) and Y-o-Y Growth
4.5.2. Baculoviral IAP Repeat Containing Protein 5 Market Size (000 Units) and Y-o-Y Growth
4.5.3. Baculoviral IAP Repeat Containing Protein 5 Market Absolute $ Opportunity
5. Global Baculoviral IAP Repeat Containing Protein 5 Market Analysis and Forecast by Type
5.1. Market Trends
5.2. Introduction
5.2.1. Basis Point Share (BPS) Analysis by Type
5.2.2. Y-o-Y Growth Projections by Type
5.3. Baculoviral IAP Repeat Containing Protein 5 Market Size and Volume Forecast by Type
5.3.1. BKM-1740
5.3.2. BI-1361849
5.3.3. BGA-005
5.3.4. FL-118
5.3.5. Others
5.4. Absolute $ Opportunity Assessment by Type
5.5. Market Attractiveness/Growth Potential Analysis by Type
6. Global Baculoviral IAP Repeat Containing Protein 5 Market Analysis and Forecast by Application
6.1. Market Trends
6.2. Introduction
6.2.1. Basis Point Share (BPS) Analysis by Application
6.2.2. Y-o-Y Growth Projections by Application
6.3. Baculoviral IAP Repeat Containing Protein 5 Market Size and Volume Forecast by Application
6.3.1. Bone Cancer
6.3.2. Kidney Cancer
6.3.3. Ovarian Cancer
6.3.4. Breast Cancer
6.3.5. Others
6.4. Absolute $ Opportunity Assessment by Application
6.5. Market Attractiveness/Growth Potential Analysis by Application
7. Global Baculoviral IAP Repeat Containing Protein 5 Market Analysis and Forecast by Sales Channel
7.1. Market Trends
7.2. Introduction
7.2.1. Basis Point Share (BPS) Analysis by Sales Channel
7.2.2. Y-o-Y Growth Projections by Sales Channel
7.3. Baculoviral IAP Repeat Containing Protein 5 Market Size and Volume Forecast by Sales Channel
7.3.1. Manufacturer/Distributor/Service Provider
7.3.2. Aftermarket
7.4. Absolute $ Opportunity Assessment by Sales Channel
7.5. Market Attractiveness/Growth Potential Analysis by Sales Channel
8. Global Baculoviral IAP Repeat Containing Protein 5 Market Analysis and Forecast by Region
8.1. Market Trends
8.2. Introduction
8.2.1. Basis Point Share (BPS) Analysis by Region
8.2.2. Y-o-Y Growth Projections by Region
8.3. Baculoviral IAP Repeat Containing Protein 5 Market Size and Volume Forecast by Region
8.3.1. North America
8.3.2. Latin America
8.3.3. Europe
8.3.4. Asia Pacific
8.3.5. Middle East and Africa (MEA)
8.4. Absolute $ Opportunity Assessment by Region
8.5. Market Attractiveness/Growth Potential Analysis by Region
8.6. Global Baculoviral IAP Repeat Containing Protein 5 Demand Share Forecast, 2019-2029
9. North America Baculoviral IAP Repeat Containing Protein 5 Market Analysis and Forecast
9.1. Introduction
9.1.1. Basis Point Share (BPS) Analysis by Country
9.1.2. Y-o-Y Growth Projections by Country
9.2. North America Baculoviral IAP Repeat Containing Protein 5 Market Size and Volume Forecast by Country
9.2.1. U.S.
9.2.2. Canada
9.3. Absolute $ Opportunity Assessment by Country
9.4. North America Baculoviral IAP Repeat Containing Protein 5 Market Size and Volume Forecast by Application
9.4.1. Bone Cancer
9.4.2. Kidney Cancer
9.4.3. Ovarian Cancer
9.4.4. Breast Cancer
9.4.5. Others
9.5. Basis Point Share (BPS) Analysis by Application
9.6. Y-o-Y Growth Projections by Application
9.7. North America Baculoviral IAP Repeat Containing Protein 5 Market Size and Volume Forecast by Type
9.7.1. BKM-1740
9.7.2. BI-1361849
9.7.3. BGA-005
9.7.4. FL-118
9.7.5. Others
9.8. Basis Point Share (BPS) Analysis by Type
9.9. Y-o-Y Growth Projections by Type
9.10. Market Attractiveness/Growth Potential Analysis
9.10.1. By Country
9.10.2. By Product Type
9.10.3. By Application
9.10.4. By Sales Channel
9.11. North America Baculoviral IAP Repeat Containing Protein 5 Demand Share Forecast, 2019-2029
10. Latin America Baculoviral IAP Repeat Containing Protein 5 Market Analysis and Forecast
10.1. Introduction
10.1.1. Basis Point Share (BPS) Analysis by Country
10.1.2. Y-o-Y Growth Projections by Country
10.1.3. Latin America Average Pricing Analysis
10.2. Latin America Baculoviral IAP Repeat Containing Protein 5 Market Size and Volume Forecast by Country
10.2.1. Brazil
10.2.2. Mexico
10.2.3. Rest of Latin America
10.3. Absolute $ Opportunity Assessment by Country
10.4. Latin America Baculoviral IAP Repeat Containing Protein 5 Market Size and Volume Forecast by Application
10.4.1. Bone Cancer
10.4.2. Kidney Cancer
10.4.3. Ovarian Cancer
10.4.4. Breast Cancer
10.4.5. Others
10.5. Basis Point Share (BPS) Analysis by Application
10.6. Y-o-Y Growth Projections by Application
10.7. Latin America Baculoviral IAP Repeat Containing Protein 5 Market Size and Volume Forecast by Type
10.7.1. BKM-1740
10.7.2. BI-1361849
10.7.3. BGA-005
10.7.4. FL-118
10.7.5. Others
10.8. Basis Point Share (BPS) Analysis by Type
10.9. Y-o-Y Growth Projections by Type
10.10. Market Attractiveness/Growth Potential Analysis
10.10.1. By Country
10.10.2. By Product Type
10.10.3. By Application
10.10.4. By Sales Channel
10.11. Latin America Baculoviral IAP Repeat Containing Protein 5 Demand Share Forecast, 2019-2029
11. Europe Baculoviral IAP Repeat Containing Protein 5 Market Analysis and Forecast
11.1. Introduction
11.1.1. Basis Point Share (BPS) Analysis by Country
11.1.2. Y-o-Y Growth Projections by Country
11.1.3. Europe Average Pricing Analysis
11.2. Europe Baculoviral IAP Repeat Containing Protein 5 Market Size and Volume Forecast by Country
11.2.1. Germany
11.2.2. France
11.2.3. Italy
11.2.4. U.K.
11.2.5. Spain
11.2.6. Russia
11.2.7. Rest of Europe
11.3. Absolute $ Opportunity Assessment by Country
11.4. Europe Baculoviral IAP Repeat Containing Protein 5 Market Size and Volume Forecast by Application
11.4.1. Bone Cancer
11.4.2. Kidney Cancer
11.4.3. Ovarian Cancer
11.4.4. Breast Cancer
11.4.5. Others
11.5. Basis Point Share (BPS) Analysis by Application
11.6. Y-o-Y Growth Projections by Application
11.7. Europe Baculoviral IAP Repeat Containing Protein 5 Market Size and Volume Forecast by Type
11.7.1. BKM-1740
11.7.2. BI-1361849
11.7.3. BGA-005
11.7.4. FL-118
11.7.5. Others
11.8. Basis Point Share (BPS) Analysis by Type
11.9. Y-o-Y Growth Projections by Type
11.10. Market Attractiveness/Growth Potential Analysis
11.10.1. By Country
11.10.2. By Product Type
11.10.3. By Application
11.10.4. By Sales Channel
11.11. Europe Baculoviral IAP Repeat Containing Protein 5 Demand Share, 2019-2029
12. Asia Pacific Baculoviral IAP Repeat Containing Protein 5 Market Analysis and Forecast
12.1. Introduction
12.1.1. Basis Point Share (BPS) Analysis by Country
12.1.2. Y-o-Y Growth Projections by Country
12.1.3. Asia Pacific Average Pricing Analysis
12.2. Asia Pacific Baculoviral IAP Repeat Containing Protein 5 Market Size and Volume Forecast by Country
12.2.1. China
12.2.2. Japan
12.2.3. South Korea
12.2.4. India
12.2.5. Australia
12.2.6. Rest of Asia Pacific (APAC)
12.3. Absolute $ Opportunity Assessment by Country
12.4. Asia Pacific Baculoviral IAP Repeat Containing Protein 5 Market Size and Volume Forecast by Application
12.4.1. Bone Cancer
12.4.2. Kidney Cancer
12.4.3. Ovarian Cancer
12.4.4. Breast Cancer
12.4.5. Others
12.5. Basis Point Share (BPS) Analysis by Application
12.6. Y-o-Y Growth Projections by Application
12.7. Asia Pacific Baculoviral IAP Repeat Containing Protein 5 Market Size and Volume Forecast by Type
12.7.1. BKM-1740
12.7.2. BI-1361849
12.7.3. BGA-005
12.7.4. FL-118
12.7.5. Others
12.8. Basis Point Share (BPS) Analysis by Type
12.9. Y-o-Y Growth Projections by Type
12.10. Market Attractiveness/Growth Potential Analysis
12.10.1. By Country
12.10.2. By Product Type
12.10.3. By Application
12.10.4. By Sales Channel
12.11. Asia Pacific Baculoviral IAP Repeat Containing Protein 5 Demand Share, 2019-2029
13. Middle East & Africa Baculoviral IAP Repeat Containing Protein 5 Market Analysis and Forecast
13.1. Introduction
13.1.1. Basis Point Share (BPS) Analysis by Country
13.1.2. Y-o-Y Growth Projections by Country
13.1.3. Asia Pacific Average Pricing Analysis
13.2. Middle East & Africa Baculoviral IAP Repeat Containing Protein 5 Market Size and Volume Forecast by Country
13.2.1. Saudi Arabia
13.2.2. South Africa
13.2.3. UAE
13.2.4. Rest of Middle East & Africa (MEA)
13.3. Absolute $ Opportunity Assessment by Country
13.4. Middle East & Africa Baculoviral IAP Repeat Containing Protein 5 Market Size and Volume Forecast by Application
13.4.1. Bone Cancer
13.4.2. Kidney Cancer
13.4.3. Ovarian Cancer
13.4.4. Breast Cancer
13.4.5. Others
13.5. Basis Point Share (BPS) Analysis by Application
13.6. Y-o-Y Growth Projections by Application
13.7. Middle East & Africa Baculoviral IAP Repeat Containing Protein 5 Market Size and Volume Forecast by Type
13.7.1. BKM-1740
13.7.2. BI-1361849
13.7.3. BGA-005
13.7.4. FL-118
13.7.5. Others
13.8. Basis Point Share (BPS) Analysis by Type
13.9. Y-o-Y Growth Projections by Type
13.10. Market Attractiveness/Growth Potential Analysis
13.10.1. By Country
13.10.2. By Product Type
13.10.3. By Application
13.10.4. By Sales Channel
13.11. Middle East & Africa Baculoviral IAP Repeat Containing Protein 5 Demand Share, 2019-2029
14. Competition Landscape
14.1. Global Baculoviral IAP Repeat Containing Protein 5 Market: Market Share Analysis
14.2. Baculoviral IAP Repeat Containing Protein 5 Distributors and Customers
14.3. Baculoviral IAP Repeat Containing Protein 5 Market: Competitive Dashboard
14.4. Company Profiles (Details Overview, Financials, Developments, Strategy)
14.4.1. Biomics Biotechnologies Co Ltd
14.4.1.1. Overview
14.4.1.2. Financials
14.4.1.3. Developments
14.4.1.4. Strategic Outlook
14.4.2. Bioneer Corp
14.4.2.1. Overview
14.4.2.2. Financials
14.4.2.3. Developments
14.4.2.4. Strategic Outlook
14.4.3. Boehringer Ingelheim GmbH
14.4.3.1. Overview
14.4.3.2. Financials
14.4.3.3. Developments
14.4.3.4. Strategic Outlook
14.4.4. Immunovaccine Inc
14.4.4.1. Overview
14.4.4.2. Financials
14.4.4.3. Developments
14.4.4.4. Strategic Outlook
14.4.5. MimiVax LLC
14.4.5.1. Overview
14.4.5.2. Financials
14.4.5.3. Developments
14.4.5.4. Strategic Outlook
14.4.6. Optimum Therapeutics LLC
14.4.6.1. Overview
14.4.6.2. Financials
14.4.6.3. Developments
14.4.6.4. Strategic Outlook
14.4.7. Polyplus-Transfection SA
14.4.7.1. Overview
14.4.7.2. Financials
14.4.7.3. Developments
14.4.7.4. Strategic Outlook
14.4.8. Stemline Therapeutics Inc
14.4.8.1. Overview
14.4.8.2. Financials
14.4.8.3. Developments
14.4.8.4. Strategic Outlook
14.4.9. tella Inc
14.4.9.1. Overview
14.4.9.2. Financials
14.4.9.3. Developments
14.4.9.4. Strategic Outlook
14.4.10. Vaxeal Holding SA
14.4.10.1. Overview
14.4.10.2. Financials
14.4.10.3. Developments
14.4.10.4. Strategic Outlook
14.4.11. COMPANY 11
14.4.11.1. Overview
14.4.11.2. Financials
14.4.11.3. Developments
14.4.11.4. Strategic Outlook
14.4.12. COMPANY 12
14.4.12.1. Overview
14.4.12.2. Financials
14.4.12.3. Developments
14.4.12.4. Strategic Outlook
14.4.13. COMPANY 13
14.4.13.1. Overview
14.4.13.2. Financials
14.4.13.3. Developments
14.4.13.4. Strategic Outlook
14.4.14. COMPANY 14
14.4.14.1. Overview
14.4.14.2. Financials
14.4.14.3. Developments
14.4.14.4. Strategic Outlook
14.4.15. COMPANY 15
14.4.15.1. Overview
14.4.15.2. Financials
14.4.15.3. Developments
14.4.15.4. Strategic Outlook
14.4.16. COMPANY 16
14.4.16.1. Overview
14.4.16.2. Financials
14.4.16.3. Developments
14.4.16.4. Strategic Outlook
14.4.17. COMPANY 17
14.4.17.1. Overview
14.4.17.2. Financials
14.4.17.3. Developments
14.4.17.4. Strategic Outlook
14.4.18. COMPANY 18
14.4.18.1. Overview
14.4.18.2. Financials
14.4.18.3. Developments
14.4.18.4. Strategic Outlook
14.4.19. COMPANY 19
14.4.19.1. Overview
14.4.19.2. Financials
14.4.19.3. Developments
14.4.19.4. Strategic Outlook
14.4.20. COMPANY 20
14.4.20.1. Overview
14.4.20.2. Financials
14.4.20.3. Developments
&n
